Publication

Upfront autologous stem cell transplantation (ASCT) Vs carfilzomib-cyclophosphamide-dexamethasone (KCD) consolidation in transplant-eligible, newly diagnosed (NDTE) multiple myeloma (MM): results of the cardamon study according to cytogenetic risk

Yong, K.
; 
Wilson, W.
; 
Camilleri, M.
; 
Ramasamy, K.
; 
Streetly, M.
; 
Sive, J.
; 
Bygrave, C. A.
; 
Chapman, M.
; 
de Tute, R. M.
; 
Chavda, S. J.
... show 10 more
Citations
Altmetric:
Abstract
Authors
Yong, K.
Wilson, W.
Camilleri, M.
Ramasamy, K.
Streetly, M.
Sive, J.
Bygrave, C. A.
Chapman, M.
de Tute, R. M.
Chavda, S. J.
Phillips, Elizabeth H
Cuadrado, M. D. M.
Pang, G.
Jenner, R.
Dadaga, T.
Kamora, S.
Cavenagh, J.
Clifton-Hadley, L.
Owen, R. G.
Popat, R.
Affiliation
Cancer Institute, Department of Haematology, University College London, London, United Kingdom
Description
Date
2021
Publisher
Collections
All Paterson Institute for Cancer Research
Show all metadata
Keywords
Type
Meetings and Proceedings
Citation
Yong K, Wilson W, Camilleri M, Ramasamy K, Streetly M, Sive J, et al. Upfront Autologous Stem Cell Transplantation (ASCT) Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Consolidation in Transplant-Eligible, Newly Diagnosed (NDTE) Multiple Myeloma (MM): Results of the Cardamon Study According to Cytogenetic Risk. Blood. 2021 Nov;138. PubMed PMID: WOS:000736413903204.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/625650
Embedded videos